Alpha 2.0
Login Register
» Authors » N Haj Mohammad

N Haj Mohammad

Explore the profile of N Haj Mohammad including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 378
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
H W M van Laarhoven
J P Ruurda
R van Hillegersberg
J W Wilmink
M W J Stommel
H C van Santvoort
M G H van Oijen
I Q Molenaar
M G Besselink
L A A Brosens
Published In
Trials
Eur J Surg Oncol
Ann Surg Oncol
Gastric Cancer
Support Care Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Endobronchial Ultrasonography to Assess and Evaluate Tracheobronchial Tree Invasion in cT4b Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: Assessment of Resectability
Defize I, de Groot E, van de Langerijt O, van Velzen M, Mook S, Haj Mohammad N, et al.
Ann Surg Oncol . 2024 Jul; 32(1):284-292. PMID: 38971953
Background: In cT4b esophageal cancer, accurate assessment of tracheobronchial tree invasion after definitive chemoradiotherapy (dCRT) aids in the selection of patients for whom an oncologic radical esophagectomy can be achieved....
2.
Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within...
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jul; 25(1):456. PMID: 38970096
No abstract available.
3.
Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design
Daamen L, van Goor I, Groot V, Andel P, Brosens L, Busch O, et al.
Trials . 2024 Jun; 25(1):401. PMID: 38902836
Background: Disease recurrence remains one of the biggest concerns in patients after resection of pancreatic ductal adenocarcinoma (PDAC). Despite (neo)adjuvant systemic therapy, most patients experience local and/or distant PDAC recurrence...
4.
Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study
Luijten J, Vissers P, Brom L, de Bievre M, Buijsen J, Rozema T, et al.
BMC Health Serv Res . 2022 Apr; 22(1):527. PMID: 35449018
Background: Among esophagogastric cancer patients, the probability of having undergone treatment with curative intent has been shown to vary, depending on the hospital of diagnosis. However, little is known about...
5.
Prognostic value of patient-reported quality of life for survival in oesophagogastric cancer: analysis from the population-based POCOP study
van Kleef J, Dijksterhuis W, van den Boorn H, Prins M, Verhoeven R, Gisbertz S, et al.
Gastric Cancer . 2021 Jul; 24(6):1203-1212. PMID: 34251543
Background: Accumulating evidence of trials demonstrates that patient-reported health-related quality of life (HRQoL) at diagnosis is prognostic for overall survival (OS) in oesophagogastric cancer. However, real-world data are lacking. Moreover,...
6.
Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial
Walma M, Rombouts S, Brada L, Borel Rinkes I, Bosscha K, Bruijnen R, et al.
Trials . 2021 Apr; 22(1):313. PMID: 33926539
Background: Approximately 80% of patients with locally advanced pancreatic cancer (LAPC) are treated with chemotherapy, of whom approximately 10% undergo a resection. Cohort studies investigating local tumor ablation with radiofrequency...
7.
Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy
Defize I, van der Horst S, Bulbul M, Haj Mohammad N, Mook S, Meijer G, et al.
Ann Surg Oncol . 2020 Dec; 28(5):2730-2738. PMID: 33341917
Background: Patients  with esophageal cancer  that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive chemoradiotherapy (dCRT). dCRT might result in sufficient downstaging to enable a...
8.
The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry
Brada L, Walma M, van Dam R, de Vos-Geelen J, de Hingh I, Creemers G, et al.
Pancreatology . 2020 Dec; 21(1):163-169. PMID: 33309624
Background: The treatment options for patients with locally advanced pancreatic cancer (LAPC) have improved in recent years and consequently survival has increased. It is unknown, however, if elderly patients benefit...
9.
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials
Belkouz A, Wilmink J, Haj Mohammad N, Hagendoorn J, de Vos-Geelen J, Dejong C, et al.
Crit Rev Oncol Hematol . 2020 May; 151:102975. PMID: 32464483
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have...
10.
MSI as a predictive factor for treatment outcome of gastroesophageal adenocarcinoma
van Velzen M, Derks S, van Grieken N, Haj Mohammad N, van Laarhoven H
Cancer Treat Rev . 2020 May; 86:102024. PMID: 32388292
Gastroesophageal cancers are a major cause of death worldwide and treatment outcomes remain poor. Adequate predictive biomarkers have not been identified. Microsatellite instability (MSI) as a result of mismatch repair...